Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC.

IF 3 3区医学 Q2 ONCOLOGY

Investigational New Drugs Pub Date : 2024-12-16 DOI:10.1007/s10637-024-01487-3

LinRui Ma, WeiKang Meng, WenJuan Jiang

引用次数: 0

查看原文本刊更多论文

Vebreltinib：METex14突变型非小细胞肺癌靶向治疗的里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Investigational New Drugs 医学-药学

CiteScore

7.60

自引率

0.00%

发文量

121

审稿时长

1 months

期刊介绍： The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.